Tissue Factor and Systemic Lupus Erythematosus Compncated by Atherosclerotic Lesions

We should grasp the entirety when studying the pathogenesis and treatment of disease.The pathogenesis of SLE pafients with atherosclerosis (AS)involves lipid infiltration,inflammatory reaction,immune injury,platelet aggregafion,thrombosis,etc,and the drug therapy includes lipid-lowering,anti-inflammatory,immunosuppression,anti-platelet,and anticoagulation based on corresponding theories.But these drugs,the effect of which is not ideal,principally aim at just part of pathological process.In fact,the AS lesioas in SLE in different pathological processes are closely linked,and therefore,it is very important to study the internal relations of different pathological processes and lookfor new therapeutic targets for blocking difierent pathological processes simultaneously,so as to improve the therapeutic efficacy.

Cancer and Thrombosis

Relationship between cancer and thromboembolic disease, the research has been going on for more than a century.Armand trousseau in 1865 first reported the formation of venous thrombosis prone patients with gastric cancer.

A Ttach lmportance to Vascular lmplications of Kruppel-like Factors

Kruppel-like factors(KLFs) are a subclass of the zinc finger family of DNA-binding transcription factors. The nomenclature is based on the homology to the DNA-binding domain of the drosophila protein kruppel. To date,17 members of KLF family have been identified in mammalian cells.

Thrombin Activable Fibrinolysis Inhibitor

The zymogen thrombin activable fibrinolysis inhibi-tor (TAFI), also known as procarboxypeptidase U (proCPU), was first described by Hendriks and cowork-ers in 1989.

Platelet-Leukocyte Interaction and Thrombosis

Cerebrocardiac thrombotic disease such as acute myocardial infarction and acute ischemic stroke cause signifieant morbidity and mortality.Present therapies for these diseases besides anticoagulation and fibrinolysis mainly aim toward limiting platelet adhesion and aggregation processes.However,their incomplete effectiveness suggests that other mechanisms may be important.

Thromboembotic events are being increasingly diagnosed in children. The incidence of symptomatic thrombolic events is 0.07%/10 000 children , 5.3/10 000hospital admissions of children and 2.4/1 000 admissions of newborns to intensive care units in west, but the incidence of thromboembotic events in children in China is an unknow now.

Cancer and Thrombosis

Since 1865, Aremand Trousseau first reported on the association between cancer and thrombosis. For many years, it has been recognized that venous thromboembolism (VTE) is a common occurrence in patients with malignant disease. Compared to other groups of patients with VTE the cancer population is unique because the pathogenesis of thrombosis differs, the frequency of VTE is greater and the clinical management required is more complex.